Shock & Awe Valuations - Is Biotech In a Bull Market?

Dr. Mark Charest, LifeSci Partners, spent some time with us talking about a wide range of topics:

Some of the topics covered:

• Is biotech finally coming out of the doldrums?

• How has recent M&A compared to 2021 and 2022?

• Is "creative destruction" going to continue with rates at these levels?

• Will banking issues impact biotech?

• Is the regulatory environment a headwind or a tailwind?

• Why are firms seeming to "overpay" for acquisitions?

A quick 13-minute conversation definitely worth your time...